NCT00816972

Desloratadine With Oxybutynin for the Treatment of Seasonal Allergic Rhinitis and Post-Nasal Drip (Study P04258)(COMPLETED)

Pilot Efficacy and Safety Field Trial of Desloratadine Administered Concomitantly With Oxybutynin, in Subjects With Seasonal Allergic Rhinitis and Post-Nasal Drip

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 540 (actual)
• Sponsor: Organon and Co · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This was a 1-week study of desloratadine (DL) plus oxybutynin (OXY) at two dose levels in the treatment of post-nasal drip in participants with seasonal allergic rhinitis. Participants received either desloratadine twice a day, oxybutynin twice a day, desloratadine plus lower-dose oxybutynin twice a day, desloratadine plus higher-dose oxybutynin twice a day, or placebo for 7 days.

Conditions

• Post-nasal Drip
• Seasonal Allergic Rhinitis
• Rhinorrhea

Interventions

Type	Name	Description
DRUG	Desloratadine 2.5 mg	Desloratadine 2.5 mg BID
DRUG	Oxybutynin 2.5 mg	Oxybutynin 2.5 mg BID
DRUG	Placebo for Desloratadine 2.5 mg	Placebo BID
DRUG	Placebo for Oxybutynin 2.5 mg	Placebo BID

Timeline

• Start date: 2005-04-01
• Primary completion: 2005-06-01
• Completion: 2005-06-01
• First posted: 2009-01-06
• Last updated: 2022-02-16